VOLTAS brings ETO sterilization in-house to cut validation time in half

VOLTAS says its new in-house ethylene oxide sterilization service gives medical device makers a faster validation path at the same cost as outsourced work. The Minnesota company says the setup can reduce sterilization validation timelines by 50% while keeping assembly, packaging, documentation, and sterilization under one roof.

Why it matters: - Medical device makers often lose time when sterilization is outsourced, because products must move to another facility, wait for outside scheduling, and then return for documentation and validation steps. - VOLTAS says bringing ethylene oxide sterilization in-house cuts the validation timeline by 50% at no additional cost, which can speed development and commercialization for single-use devices that cannot withstand heat or radiation.

What happened: - VOLTAS launched in-house ethylene oxide sterilization services at its ISO 13485-compliant facility in Cottage Grove, Minnesota. - The company says the service is available now to startups and established device manufacturers. - VOLTAS says the offering supports both development-stage builds and ongoing commercial volumes.

The details: - The sterilization capability covers runs from small routine batches to full pallet sterilization. - Services include in-house ETO sterilization, sterile barrier packaging and labeling, full sterilization validation, cycle development, cleanroom assembly through sterilization, and regulatory documentation support. - VOLTAS says a device can move from cleanroom assembly through a validated ETO cycle without leaving the building. - The company says that setup preserves full traceability throughout the process. - VOLTAS says the same project team handles sterilization alongside cleanroom assembly, packaging, and regulatory work. - The company says that single-team structure reduces handoffs between vendors. - VOLTAS says it supports terminal sterilization for single-use devices, hardest-to-sterilize studies, and commercial production.

Between the lines: - The move positions VOLTAS as a more integrated manufacturing partner for device companies that want fewer external dependencies. - The in-house model also appears designed to reduce translation loss that can happen when device development, packaging, and sterilization sit with separate vendors. - The company’s broader service list shows a push to cover more of the product lifecycle, from R&D and regulatory work to manufacturing, coating, sterilization, marketing, and sales.

What's next: - VOLTAS is now offering the sterilization service as part of its broader development and manufacturing platform. - Device makers working with VOLTAS can use the company’s regulatory documentation support to help keep submissions and audits on track. - More information is available at the company’s announcement and on VOLTAS on LinkedIn.

The bottom line: - VOLTAS is betting that faster validation, fewer handoffs, and one documentation trail will make in-house ETO sterilization a better fit for medical device teams than the outsourced model.